WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015125956) METHOD FOR PREDICTING RESPONSIVENESS TO CANCER TREATMENT USING p300-INHIBITING COMPOUND
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2015/125956 International Application No.: PCT/JP2015/054991
Publication Date: 27.08.2015 International Filing Date: 23.02.2015
IPC:
C12N 15/09 (2006.01) ,A61P 35/00 (2006.01) ,C12Q 1/68 (2006.01) ,G01N 33/15 (2006.01) ,G01N 33/50 (2006.01)
Applicants: NATIONAL CANCER CENTER[JP/JP]; 5-1-1, Tsukiji, Chuo-ku, Tokyo 1040045, JP
DAIICHI SANKYO COMPANY, LIMITED[JP/JP]; 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 1038426, JP
Inventors: KOHNO Takashi; JP
OGIWARA Hideaki; JP
TOMINAGA Yuichi; JP
HIGUCHI Saito; JP
Agent: CENTCREST IP ATTORNEYS; Kikuya Bldg. 9th Floor, 2-8-21, Kyobashi, Chuo-ku, Tokyo 1040031, JP
Priority Data:
2014-03292824.02.2014JP
Title (EN) METHOD FOR PREDICTING RESPONSIVENESS TO CANCER TREATMENT USING p300-INHIBITING COMPOUND
(FR) MÉTHODE PERMETTANT DE PRÉVOIR LA SENSIBILITÉ À UN TRAITEMENT ANTICANCÉREUX AU MOYEN D'UN COMPOSÉ INHIBITEUR DE p300
(JA) p300を阻害する化合物によるがんの治療への応答性を予測する方法
Abstract:
(EN)  CBP and p300 are synthetically lethal, and treatment that inhibits p300 can be a promising approach for treating CBP mutation-type cancer. In this treatment strategy, cancer patients can be selected using CBP function suppression as a marker, and then administered a p300 inhibitor, whereby efficient treatment based on companion diagnostics is possible.
(FR)  Selon l'invention, CBP et p300 sont synthétiquement létaux, et le traitement qui inhibe p300 peut être une approche prometteuse dans le traitement du cancer de type à mutations du CBP. Dans cette stratégie de traitement, des patients atteints du cancer peuvent être sélectionnés en fonction d'une suppression de la fonction du CBP servant de marqueur, puis recevoir un inhibiteur de p300, ce qui permet d'obtenir un traitement efficace au moyen de diagnostics associés.
(JA)  CBPとp300が合成致死の関係にあり、p300を阻害する治療がCBP変異型がんの治療のための有望なアプローチになることを見出した。また、この治療戦略においては、がん患者をCBPの機能抑制を指標に選別した上で、p300阻害剤を投与できるため、コンパニオン診断に基づく効率的な治療が可能であることも明らかとなった。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)